Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration

Details

• Personal Author:
  Couch, James R. ; Fleury AC ; Hill MC ; Kushnir CL ; Spirtos NM
• Description:
  Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. In 2006, the National Cancer Institute released an announcement supporting the use of intraperitoneal (IP) chemotherapy in advanced ovarian cancer. It remains unanswered how many cycles of IP chemotherapy are required to maintain a survival advantage. There may be a benefit with as few as three IP cycles and possibly as few as one IP chemotherapy cycle. Objective. In preparation for a clinical trial in which chemotherapy would be administered intraoperatively, the question of exposure to healthcare personnel arose, therefore, the purpose of this study was to perform an evaluation of healthcare personnel exposure to cisplatin during a mock demonstration of intraperitoneal chemotherapy administration. Materials and methods. The National Institute of Occupational Safety and Health (NIOSH), the Women's Cancer Center of Nevada, and the staff of the University Medical Center, Las Vegas, participated in this mock demonstration. Employees wore personal protective equipment recommended by NIOSH. Wipe, area, and breathing zone air samples were taken from the pharmacy and operating room, and during sterilization of equipment. Results. All samples were negative for cisplatin, except for one surface wipe from the floor of the operating room (OR) after the mock procedure. Upon sanitization of the OR, no cisplatin was detected on the floor. Conclusion. This was the first study evaluating the exposure of healthcare personnel to the administration of cisplatin intra-operatively. NIOSH endorsed this practice so long as the employees adhere to using the recommended personal protective equipment. [Description provided by NIOSH]
• Subjects:
  Drug Therapy Environmental Monitoring Hazardous Substances Health Personnel Neoplasms Occupational Exposure Occupational Health Operating Rooms Personal Protective Equipment Safety
• Keywords:
  Advanced Ovarian Cancer Air-sampling Author Keywords: Intraperitoneal Chemotherapy Breathing-zone Cancer Chemotherapy Cisplatin Drug-therapy Employee-exposure Exposure-assessment Gynecological-disorders Hazardous-materials Health-care-personnel Healthcare Safety Medical-treatment Oncogenic-agents Operating-rooms Optimal Cytoreductive Surgery Personal-protective-equipment Personal Protective Equipment Pharmacy-workers Safety-practices Sampling Simulation-methods Work-operations Work-performance Worker-health

  More +
• ISSN:
  0090-8258
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  Maryland ; Nevada ; Ohio ; OSHA Region 3 ; OSHA Region 5 ; OSHA Region 9
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  DSHEFS - Division of Surveillance, Hazard Evaluations, and Field Studies
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  350-353
• Volume:
  130
• Issue:
  2
• NIOSHTIC Number:
  nn:20043057
• Citation:
  Gynecol Oncol 2013 Aug; 130(2):350-353
• Contact Point Address:
  Christina L. Kushnir, The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, MD 21287, USA
• Email:
  kushnir22@live.com
• CAS Registry Number:
  Cisplatin (CAS RN 15663-27-1)
• Federal Fiscal Year:
  2013
• Peer Reviewed:
  True
• Source Full Name:
  Gynecologic Oncology
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:bb0aedd4603cb5676701c41042f01e3fcabe56e7962c21beda812b691cb3a4b76e603928008b7268d1e55ecab0f105a5b53de9052dc0728ffc082c7b1ba364fe
• Download URL:
  https://stacks.cdc.gov/view/cdc/195077/cdc_195077_DS1.pdf
• File Type:
  [PDF - 379.51 KB ]